Bedlington Terrier Copper Storage Disease: Comprehensive Management Guide

Copper-associated hepatopathy in Bedlington Terriers is an inherited disorder of copper excretion. Early diagnosis with genetic testing and liver biopsy plus chelation, zinc and a low-copper diet yield good outcomes.

Quick Overview

• What it is: Copper-associated hepatopathy (also called copper storage disease) is an inherited disorder in Bedlington Terriers in which defective biliary copper excretion causes progressive hepatic copper accumulation, liver inflammation and potentially cirrhosis.
• Who's at risk: Bedlington Terriers are at high risk due to an autosomal recessive deletion of the COMMD1 (formerly MURR1/COMM domain) gene. Affected dogs inherit two abnormal copies; carriers have one copy and are clinically normal but can pass the mutation on.
• Prognosis: With early detection and proper management (chelation, zinc therapy and a copper-restricted diet), many dogs stabilize or improve clinically; advanced cirrhosis or hepatic failure carries a guarded to poor prognosis.

Why this guide matters

Bedlington Terriers were one of the first dog breeds in which a specific genetic cause for copper toxicosis was identified. Understanding genetics, accurate diagnosis and a combined medical/dietary approach can prevent progression and preserve quality of life.

Pathophysiology (simple explanation)

• Normal physiology: The liver takes up dietary copper, uses some for enzymes, stores some bound to metallothionein, and excretes excess copper into bile.
• In Bedlington Terriers: Deletion of the COMMD1 gene impairs biliary copper excretion. Copper accumulates inside hepatocytes, producing oxidative injury, inflammation (hepatitis), cell death and eventually fibrosis/cirrhosis.
• Clinical consequence: Copper itself is not inert—excess free copper catalyzes oxidative damage to membranes and cellular components, provoking inflammation and progressive liver dysfunction.

• Genetics: The Bedlington Terrier copper storage problem is inherited in an autosomal recessive pattern due to a COMMD1 gene deletion. Affected dogs are homozygous for the deletion; heterozygous dogs are carriers.
• Population impact: Historically, many lines had high carrier rates; widespread DNA testing and selective breeding programs have reduced but not eliminated the mutation frequency in some populations. If you own or plan to breed Bedlingtons, genetic testing is essential to avoid producing affected puppies (see Diagnostic section).

• Early stage (subclinical): Many affected dogs are clinically normal for months to years; clinicopathologic abnormalities (mild elevations in ALT/AST) are often the first clue.
• Progressive hepatitis: Lethargy, poor appetite, vomiting, weight loss, intermittent diarrhea and increased liver enzymes.
• Advanced disease (cirrhosis/hepatic failure): Jaundice, ascites, coagulopathy (bleeding), hepatic encephalopathy (disorientation, seizures), and severe weight loss.
• Acute hemolytic episodes: Rarely, sudden hemolytic crises have been reported in copper-overloaded dogs; this can present as pale or jaundiced mucous membranes and dark urine.

1) Screening and genetic testing

• Genetic test for COMMD1 deletion: inexpensive and simple (blood or cheek swab). Identifies affected dogs and carriers. All Bedlington Terriers intended for breeding should be tested. A positive homozygous result confirms genetic risk but does not replace liver evaluation for disease stage.

• Routine panel: CBC, serum biochemistry (ALT, AST, ALP, bilirubin), albumin, coagulation profile (PT, aPTT) if liver disease is suspected.
• Note: Normal bloodwork does not exclude substantial hepatic copper—many dogs are subclinical.

• Abdominal ultrasound: can identify changes compatible with chronic liver disease (nodularity, size change, ascites) and guide biopsy choice but cannot quantify copper.

• Why biopsy: Histopathology demonstrates hepatic inflammation, necrosis and fibrosis, and allows quantitative measurement of hepatic copper concentration (the gold standard).
• Quantitative copper: Measured on liver tissue (dry weight) by atomic absorption spectroscopy or ICP-MS. Interpretation commonly used in veterinary hepatology:

• Sampling and referral: A board-certified veterinary internal medicine specialist or veterinary surgeon should perform biopsy (ultrasound-guided tru-cut or surgical wedge); discuss risks (bleeding) and need to check coagulation first.

The treatment strategy is twofold: 1) Remove excess copper (chelation) if hepatic copper is high or the dog is clinically ill. 2) Prevent re-accumulation (zinc therapy + copper-restricted diet) once copper is reduced.

Medical chelation

1) D-penicillamine (first-line in many cases)

• Mechanism: Binds copper to form a complex excreted in urine.
• Typical dosing concept: 10–20 mg/kg PO every 12 hours (many protocols use 10–15 mg/kg q12h). Start on an empty stomach if tolerated (improves absorption) and separate from zinc by several hours because zinc interferes with absorption.
• Expected response: Decrease in serum liver enzymes and urinary copper excretion usually within weeks; hepatic copper decreases over months. Treatment often continues for 6–12 months or longer until hepatic copper is below target on repeat biopsy.
• Side effects: Gastrointestinal upset (nausea, vomiting), skin reactions, lymphadenopathy, possible nephrotoxicity or proteinuria, bone marrow suppression (rare). Monitor CBC, urinalysis (protein), renal values regularly.
• Notes: Because penicillamine can cause adverse effects, dose adjustments or switching therapy may be required.

• Mechanism: Chelates copper with fewer allergic side effects in some patients.
• Use: Considered when dogs cannot tolerate penicillamine.
• Dosing concept: Veterinary dosing is less standardized; commonly used ranges in the veterinary literature are in the order of multiple daily doses with total daily doses approximately similar to penicillamine on a mg/kg basis (e.g., 20–30 mg/kg/day divided q8–12h), but veterinary specialist input is required to set dose and schedule.
• Side effects: Generally better tolerated but can still cause GI signs and requires monitoring.

• Monitoring: CBC, biochemistry, urinalysis every 2–8 weeks during early therapy, then less often once stable. Repeat liver biopsy and hepatic copper measurement is the most reliable way to determine when chelation can be stopped; many clinicians repeat biopsy after 6–12 months of chelation or when biochemical markers have normalized.
• Specialist referral: Strongly recommended for dosing and monitoring guidance and for managing side effects.

• Mechanism: Zinc induces intestinal metallothionein that preferentially binds copper in enterocytes, reducing copper absorption.
• When to use: Often used as long-term maintenance therapy after chelation, and in some dogs with mild accumulation as initial therapy when inflammation is minimal. Also helpful for lifelong prevention of re-accumulation.
• Dosing concept: Veterinary preparations used include zinc sulfate, zinc acetate or zinc gluconate. Typical veterinary protocols provide elemental zinc in divided doses (commonly twice daily); exact mg/kg elemental zinc dosing varies by protocol. Your veterinarian or specialist will prescribe a formulation and dose appropriate for your dog and monitor for toxicity.
• Side effects and monitoring: GI upset can occur; prolonged high zinc dosing can cause copper deficiency and other metabolic issues, so periodic monitoring (CBC, biochemistry) is required.

• Rationale: Reduce intestinal copper intake so that losses (bile and chelation) exceed intake, preventing re-accumulation.
• Practical advice:

• Duration: Usually lifelong maintenance once copper has been controlled.

• Liver transplant: Rarely performed in dogs and available at a few referral centers; indicated for end-stage liver failure in selected cases but is complex, costly and limited in availability.

• Recheck schedule: Initially every 2–8 weeks while on chelation to monitor clinical response and treatment side effects; once stable, extend intervals (e.g., every 3–6 months).
• Laboratory monitoring: ALT/AST, bilirubin, albumin, CBC, renal values and urinalysis (monitor for proteinuria with penicillamine). Monitor coagulation prior to invasive procedures.
• Repeat liver biopsy: The only reliable method to confirm hepatic copper reduction. Many clinicians aim for hepatic copper <400 µg/g dry weight before stopping chelation and switching fully to maintenance with zinc and diet.
• Life expectancy and follow-up: Many dogs live months to years with medical management; lifelong follow-up is necessary.

• Early disease: Dogs diagnosed before significant fibrosis often respond well to chelation and diet and can have a good quality of life.
• Advanced disease: Once cirrhosis or hepatic failure develops, prognosis is guarded to poor; clinical signs may be managed palliatively for some time but progressive decline is common.
• Quality of life: Many owners report good quality of life for years when dogs receive appropriate medical therapy and dietary management. Treatment is often lifelong, but side effects are usually manageable with veterinary supervision.

• Feed only veterinary-approved low-copper diets; ask your vet for specific prescription brands.
• Avoid table scraps, organ meats and shellfish.
• Give medications exactly as prescribed; separate zinc and penicillamine doses by several hours to avoid interaction.
• Keep a medication and monitoring calendar; record appetite, vomiting, stool changes, activity and weight.
• Watch for subtle behavioral changes — early signs of hepatic encephalopathy include disorientation, repetitive licking, circling or pacing.
• Regular veterinary check-ups: don’t skip monitoring bloodwork appointments.
• If you plan to breed, work with a genetic counselor and only breed dogs with appropriate genotype (avoid producing affected puppies).

Seek immediate veterinary attention if your dog develops any of the following:

• Persistent vomiting or inappetence, severe lethargy
• Sudden onset of jaundice (yellow gums, eyes, skin)
• Blood in vomit or stool, unexplained bruising or bleeding
• Collapse, seizures, disorientation — signs of hepatic encephalopathy
• Dark or tea-colored urine, pale mucous membranes (possible hemolytic crisis)

• van de Sluis B, Rothuizen J, et al. (original genetic description of COMMD1 deletion in Bedlington Terriers). PubMed: https://pubmed.ncbi.nlm.nih.gov/11823707/
• ACVIM (American College of Veterinary Internal Medicine) — consult your local ACVIM diplomate or their resources for up-to-date consensus guidance on copper-associated hepatopathy and chronic hepatitis management.
• Published veterinary hepatology reviews and textbooks for dose ranges, monitoring recommendations and biopsy interpretation.

Frequently Asked Questions